Background {#Sec1}
==========

The deficiency of Adenosine Deaminase 2 (DADA2) is a recently identified disease, gathered in the family of autoinflammatory diseases, mainly characterised by early-onset polyarteritis, hemorrhagic and ischemic strokes and hypogammaglobulinemia.

In February 2014 two independent studies, one held by the American National Institutes of Health in Bethesda \[[@CR1]\] and the other one by the Israeli Sharee Zedek Medical Center in Jerusalem \[[@CR2]\], identified this new clinical entity, often familial, characterised by early onset livedoid rash associated with systemic inflammation (fever and elevation of acute phase reactants). Some patients presented ischemic or haemorrhagic cerebral stroke, other vasculopathy-related manifestations (hypertension, gastrointestinal symptoms), hepatosplenomegaly, peripheral neuropathy and mild immunodeficiency.

In many cases both the clinical manifestations and the histological findings were consistent with the diagnosis of polyarteritis nodosa (PAN), with childhood-onset.

The analysis of the whole exome-sequencing (WES) in unrelated affected patients identified autosomal recessive deleterious mutations in *CECR1* gene, encoding for adenosine deaminase 2 (ADA2).

The marked reduction of both plasmatic levels and enzymatic activity of ADA2 detected in affected patients respect to healthy donors \[[@CR1], [@CR2]\], confirmed the hypothesis that the causative mutation determines the loss-of-function of the protein. The non-affected simple-heterozygous parents displayed intermediate values of both plasmatic levels and enzymatic activity \[[@CR1]\].

*CECR1* gene {#Sec2}
============

The *CECR1* (Cat Eye Syndrome Chromosome Region 1) gene, mapped to chromosome 22q11.1 and constituted by 10 exons \[[@CR1], [@CR2]\], encodes for the enzyme adenosine deaminase 2 (ADA2), a protein composed by 4 domains: the signal sequence, the dimerization domain, the putative receptor-binding domain and the catalytic domain.

The mutations detected in *CECR1* gene so far are 19, with a different prevalence according to patient's ethnicity (Table [1](#Tab1){ref-type="table"}, Fig. [1](#Fig1){ref-type="fig"}) \[[@CR1]--[@CR13]\]. The G47R mutation has been detected in homozygous state in all patients of Georgian Jewish and Turkish origin. Based on the results of the molecular analysis performed in 246 healthy donors of Georgian Jewish origin, the estimated frequency of this mutation in this population is 10 % \[[@CR2]\].Table 1*CECR1* mutations so far detectedMutationExonHGVS sequence nameAminoacid substitutionN° of patientsEnzymatic domainM1T2c.2 T \> CMet1Thr1 in compound heterozygosisSignal peptideK13del2c.37_39del37_39del2 in compound heterozygosisSignal peptide (?)28-kb-deletion2deletiondeletion1 in compound heterozygosis5′UTR (5′untranslated region)G47R2c.139G \> AGly47Arg27 in homozygosisDimerization1 in compound heterozygosisG47A2c.140G \> CGly47Ala2 in compound heterozygosisDimerizationG47V2c.140G \> TGly47Val1 in compound heterozygosisDimerizationI93T2c.278 T \> CIle93Thr1 in compound heterozygosisDimerizationA109D3c.326C \> AAla109Asp1 in compound heterozygosisCatalyticH112Q3c.336C \> GHis112Gln1 in compound heterozygosisCatalyticT119A3c.355A \> GThr119Ala4 in compound heterozygosisCatalyticG142S3c.424G \> AGly142Ser4 in compound heterozygosisCatalyticR169Q3c.506G \> AArg169Gln15 in homozygosisPBR (putative receptor-binding)9 in compound heterozygosisP193L4c.578C \> TPro193Leu1 in compound heterozygosisCatalytic (?)M243R4NAMet243Arg2 in compound heterozygosisCatalyticP251L4c.752C \> TPro251Leu4 in compound heterozygosisCatalyticW264S5c.791G \> CTrp264Ser1 in compound heterozygosisCatalyticR306\*6c.916C \> Tp.Arg306\*1 in compound heterozygosisCatalytic (?)N328K7c.1159C \> ACys1159Arg2 in compound heterozygosisCatalyticY453C9c.1358A \> GTyr453Cys3 in compound heterozygosisCatalyticLegend: HGVS: Human Genome Variation Society*NA* not availableFig. 1Cat Eye Syndrome Chromosome Region 1 (*CECR1*) gene and Adenosine Deaminase 2 (ADA2) protein with the mutations by now detected

Conversely, the R169Q is the mutation more frequently detected in the European Caucasian population \[[@CR1], [@CR2], [@CR7], [@CR12], [@CR13]\].

The mutations so far detected affect the Signal peptide (*n* = 2), the 5' untranslated region (*n* = 1), the dimerization domain (*n* = 4), the putative receptor binding (*n* = 1) and the catalytic domain (*n* = 11) (Table [1](#Tab1){ref-type="table"}, Fig. [1](#Fig1){ref-type="fig"}) \[[@CR1]--[@CR13]\]. Moreover two patients with a homozygous deletion on 22.11.1 chromosome (encompassing *CECR1* gene) have been recently described \[[@CR14]\].

ADA2 protein and pathogenetic mechanisms {#Sec3}
----------------------------------------

The enzyme Adenosine Deaminase (ADA) plays a key role in the purine metabolism converting adenosine to inosine and 2′-deoxyadenosine to 2′-deoxyinosine \[[@CR15]\].

The two major ADA isoforms are ADA1, whose deficiency is cause of a severe combined immunodeficiency (SCID) \[[@CR16]\], and ADA2.

Even if the two proteins have partial structural homology, the two isoenzymes differ in many aspects: the affinity of ADA2 for molecules of adenosine and deoxy-adenosine is about 100 times lower than that of ADA1; consequently, at physiological concentrations of substrate, the deaminase activity of ADA2 is almost absent \[[@CR17]\].

While ADA1 is monomeric and acts primarily intracellularly, ADA2 is dimeric and secreted in the extracellular environment where it exerts its main functions. For this reason ADA2 is clearly detectable in the plasma. Finally, while ADA1 is ubiquitally expressed in all cell types, ADA2 is mostly expressed by monocytes and other cells of the myeloid lineage \[[@CR17]\].

ADA2 is more stable at high temperatures and the optimum pH for its activity is generally acid (about 6.5), which suggests a specialized role of this enzyme in conditions of hypoxia, inflammation and oncogenesis; in these conditions its deaminase activity is higher \[[@CR17]\] (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Production and physiological role of Adenosine Deaminase 2 (ADA2). ADA2 is produced and secreted by cells of myeloid lineage; it exerts its enzymatic activity in the extracellular space, especially in the presence of a low pH or high temperature. On monocytes (**a**) ADA2 acts as growth-factor with an autocrine activity: it induces monocytes' proliferation and promote the differentiation of M2 anti-inflammatory macrophages. On neutrophils (**b**) ADA2 induces the gene of expression of some pro-inflammatory proteins, such as myeloperoxidase (MPO) and neutrophils' activations, leading to the secretion of pro-inflammatory cytokines. There are indirect evidences of a possible role of ADA2 as growth-factor for endothelial cells (**c**)

The capacity of binding receptors involved in the signal transduction of different pathways (such as proteoglycans), confers to ADA2 a growth-factor like action; for this reason ADA2 is considered an Adenosine Deaminase-related Growth-Factor (ADGF) \[[@CR17]--[@CR19]\] (Fig. [2](#Fig2){ref-type="fig"}).

ADA2 displays also an autocrine activity: the protein, released by activated monocytes, is able to induce monocyte proliferation and macrophage differentiation \[[@CR20]\]; *CECR1* silencing in myeloid cells is in fact associated to a reduced differentiation of monocytes to macrophages \[[@CR1]\]. This activity has been demonstrated to be mediated by the direct binding of cellular receptors, and therefore to be independent from the enzymatic activity \[[@CR20]\] (Fig. [2](#Fig2){ref-type="fig"}).

ADA2 seems to be also involved in the balance between pro-inflammatory (M1) and anti-inflammatory (M2) monocytes; its absence has been in fact associated with a defect in differentiation of M2 macrophages, which leads to a prevalence of pro-inflammatory M1 cells \[[@CR1]\].

Microarray analysis in two DADA2 patients showed a marked up-regulation of neutrophils-expressed genes. Intracellular staining revealed an increased expression of myeloperoxidase (MPO) in peripheral blood mononuclear cells compared to controls \[[@CR8]\] (Fig. [2](#Fig2){ref-type="fig"}). According with these findings, the assessment of cytokine levels performed in the serum of few described patients revealed an increase of pro-inflammatory cytokines: in the two patients carrying a homozygous deletion of 22q11.1 chromosome increased levels of both IL-1β and TNFα were detected \[[@CR14]\], while in another case the detection of IL-6 revealed increased levels \[[@CR7]\]. These data are in contrast with the results obtained in the NIH study, in which the cytokine assay performed in the supernatants of the whole blood cell cultured with different stimuli did not reveal any significant difference between patients and healthy donors \[[@CR1]\]. Further studies on larger series of patients are therefore needed in order to investigate the cytokines' pattern in DADA2; in particular the cytokines' production should be assessed in stimulated PBMCs and should take into consideration the disease activity.

It has been also postulated that the deregulation of purinergic stimulation, due to the decrease of the enzymatic activity of ADA2, may play a pro-inflammatory role. Adenosine is in fact an important signaling molecule that can modulate the inflammatory response; its concentration in tissues is normally low and increases in condition of cellular stress, ischemia or inflammation \[[@CR21]\]. The accumulation of adenosine can influence the inflammatory response by binding several receptors that lead to inflammation, tissue damage and fibrosis \[[@CR21]\]. However, the plasmatic levels of adenosine and deoxiadenosine in few DADA2 patients has been detected within the normal range \[[@CR1], [@CR2]\].

Since hypogammaglobulinemia has been described in some patients, adaptive immunity has been investigated in ADA2 patients. A reduction in the number of memory B cells, terminally differentiated B cells and plasmacells has been described \[[@CR1], [@CR7]\]; moreover co-culture experiments have enlightened an increased mortality of B cells \[[@CR1]\]. Not univocal results have been detected concerning the T cells function. In fact, while in the NIH study ADA2 mutations seem not to affect T lymphocyte number and activation \[[@CR1]\], in a more recent study an increase of regulatory T cells and a decrease of CD8+ and CD4 + memory T cells have been detected in one patient with DADA2 \[[@CR7]\]. In addition a reduced number of Th1, Th2 and follicular T helper (Tfh) cells has been observed in the same patient.

The reason why endothelium represents the main target of inflammation in DADA2 is still largely unknown. ADA2 acts as a growth-factor for endothelial cells. In fact, even if it has been demonstrated that endothelial cells do not express *CECR1* gene, the deficiency of ADA2 is associated to a damage of vascular endothelium and to an over expression of activation markers \[[@CR1]\]. The knockdown animal model for *CECR1* gene (zebrafish) displays cerebral haemorrhages without morphologic alteration in the vascular structure; these episodes recovered following the transfection of non-mutant human *CECR1* messenger RNA \[[@CR1]\]. In the same way, monocytes of patients with DADA2 led to destruction of co-cultured human microvascular endothelial cells \[[@CR1]\].

Due to the rarity of the disease, all available data on the pathogenic consequences of ADA2 defect in humans come from few patients; further studies are therefore needed in order to better enlighten the activity of ADA2 in the innate and adaptive immune response and its role in the endothelium homeostasis.

Clinical manifestations {#Sec4}
-----------------------

DADA2 can be defined as an inflammatory vasculopathy with a wide range of clinical manifestations, possibly associated with an immunodeficiency of variable severity.

The disease is mainly characterized by chronic or recurrent systemic inflammation with fever and elevation of acute phase reactants, usually associated with different possible skin manifestations, ranging from the most frequent livedo reticularis (Fig. [3](#Fig3){ref-type="fig"}) to maculopapular rash, nodules, purpura, erythema nodosum, Raynaud's phenomenon, ulcerative lesions, digital necrosis \[[@CR1], [@CR2]\].Fig. 3Livedo reticularis in a patient with DADA2

The clinical picture is wide, ranging form a mild disease with a late onset skin-limited involvement to a very severe systemic phenotype (even fatal) with an early onset and a multi-organ involvement (Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}).Table 2Clinical manifestation of DADA2 patients so far describedReport*CECR1*\
MutationEthnicityAge at onsetFeverSkinCNS/PNSGastro-intestinalImmune/Hematologic systemANAANCAHypertensionOtherNavon et al.1G47R/G47RGeorgian2 mYesUlcerations at extremitiesNoIntestinal necrosisNonegnegYesCoronary aneurysms2G47R/G47RGeorgian5 yNoLivedo reticularis, nodules, purpuric rashNoIntestinal vasculitisNonegnegNoNo3G47R/G47RGeorgian7 mYesLivedo reticularis, papulo-nodular rash, Raynaud's phenomenonIschemic stroke, peripheral paresis of cranial nervesNoNonegnegYesArthritis4G47R/G47RGeorgian3,5 yYesLivedo reticularis, nodules, purpuric rash, erythema nodosumCranial nerve paralysisNoNoposNDNoNo5G47R/G47RGeorgian2,5 yNoMaculopapular rash, nodulesNeurosensorial hearing lossNoNonegnegNoArthritis6G47R/G47RGeorgian2 m (died at 9 m)YesDigital necrosisVentricular haemorrhageAneurism of celiac arteryNonegnegNoNo7G47R/G47RGeorgian2 mYesLivedo reticularis, Raynaud's phenomenonNoAbdominal painNonegNDNoNo8G47R/G47RGeorgian6,5 yYesLivedo reticularis, nodules, Raynaud's phenomenonNoAbdominal painNonegnegNoNo9G47R/G47RGeorgian9 yNoLivedo reticularisNoNoNonegnegNoNo10G47R/G47RGeorgian10 yNoLivedo reticularis, nodules, Raynaud's phenomenon, leg ulcersNoNoNonegnegNoNo11G47R/G47RGeorgian59 yNoLeg ulcersNoNoNonegNDNoNo12G47R/G47RGeorgianchildhood (died at 30 y)NoLivedo reticularis, nodules, Raynaud's phenomenon, leg ulcers with amputationNoNoNoNDNDNoNo13G47R/G47RGeorgian1 yNoLivedo reticularis, nodules, Raynaud's phenomenonSensitive polyneuropathyNoNonegnegNoNo14G47R/G47RGeorgian4 yYesLivedo reticularis, purpuric rash, skin nodules.NoNoNoposNDNoNo15G47R/G47RGeorgian1 yYesLivedo reticularisNoAbdominal painNonegnegYesMesenteric and renal infarcts16G47R/G47RGeorgian18 yNoNoNoNoNonegnegNoNo17G47R/G47RGeorgian28 yYesRaynaud's phenomenon, purpuric rash, leg ulcers with digital amputationPolyneuropathyNoNonegnegYesPanniculitis18G47R/G47RGeorgian2 yNoSkin nodulesPolyneuropathyNoNonegnegNoNo19G47R/G47RGeorgian16 yNoRaynaud's phenomenon, ulceration of extremitiesNoNoNoposnegYesNo20R169Q/P251LEuropean Caucasian1 yYesLivedo reticularisIschemic stroke, cranial nerves (II,VI,VII) paralysisNoNonegNDYesNo21R169Q/P251LEuropean Caucasian12 yNoNoIschemic stroke, VII cranial nerve paralysisNoNoposnegNoNo22R169Q/P251LEuropean Caucasian1 yNoLivedo reticularis, skin rash at extremitiesIschemic stroke\
VI cranial nerve paralysis, neurosensorial hearing lossNoNonegnegNoNo23R169Q/P251LEuropean Caucasian3 mNoLivedo reticularis, vasculitic exanthema of lower extremitiesVII cranial nerve paralysisNoNoNDNDNoEpididymitis24G47V/W264STurkish10 yYesLivedo reticularisNoNoNonegNDYesMyalgia, abdominal and renal aneurysmZhou et al.1A109D/Y453CEuropean Caucasian2 yYesLivedo reticularisIschemic strokeSplenomegalyNoposnegNoNo2G47A/Y453CEuropean Caucasian1 yYesLivedo reticularis, erythematous and urticarial rashIschemic and haemorrhagic strokesHepatomegaly, splenomegaly. Portal hypertension.Pancytopenia, hypoIgposnegNoNo3R169Q/deletionEuropean Caucasian1,5 yYesLivedo reticularis, urticarial rashIschemic and haemorrhagic strokesHepatomegaly, splenomegaly, chronic gastritisLeucopoenia, hypoIgnegnegNoNo4G47A/H112QEuropean Caucasian5 mYesLivedo reticularis, urticarial rashIschemic and haemorrhagic strokesHepatomegaly, splenomegaly, portal hypertension.Pancytopenia, HypoIgnegnegNoNo5R169Q/Y453CEuropean Caucasian1,5 yYesLivedo reticularisIschemic strokeHepatomegaly, splenomegaly.Leucopoenia, hypoIgnegnegNoNo6M1T/I93TEuropean Caucasian1,5 y (died 16 y)YesNon-Langerhans cell\
histiocytosisIschemic strokeHepatomegaly, splenomegaly. portal hypertension.NonegnegYesEvans syndrome7G47R/G47RTurkish3,5 yYesLivedo reticularis, erythema nodosumIschemic stroke\
III cranial nerve paralysisNoNonegnegNoNo8G47R/G47RTukish4 yYesLivedo reticularis, erythema nodosumIschemic strokeBowel perforationNonegnegNoMacrophage activation syndrome9G47R/G47RTurkish9 y (died 22 y)YesLivedo reticularis, ulceration of extremitiesNoHepatomegaly, splenomegalyLeucopoeniaposnegNoRenal amyloidosis, necrotising pneumoniavan Montfrans et al.1R169Q/R169QNA6 mNoLivedo reticularisNoHepatomegaly, splenomegalyGranulocytopenia, red-cell aplasiaNANANoNo2R169Q/R169QNA6 yYesLivedo reticularisStrokeHepatomegaly, splenomegalyHypoIg, lymphopeniaNANANoNoBras et al.1T119A/G142SEuropean Caucasian\>10 yYesLivedo reticularis, ulcerations of extremitiesStrokeNoNoNANANoNo2T119A/G142SEuropean Caucasian\>10 yYesLivedo reticularis, ulcerations of extremitiesStrokeNoNoNANANoNo3T119A/G142SEuropean Caucasian\>10 yYesLivedo reticularis, ulcerations of extremitiesStrokeNoNoNANANoNo4T119A/G142SEuropean Caucasian\>10 yYesLivedo reticularis, ulcerations of extremitiesStrokeNoNoNANANoNoVan Eyck et al.1G47R/G47RNA5 yYesNoNoSplenomegalyLymphadenopathy, anaemia, thrombocytosisNANANoGarg et al.1G47R/R306\*Turkish1,5 y (died 5 y)YesSkin rashHemorrhagic and ischemic stroke.\
intraparenchymal haemorrhageNoNonegnegNoAcute respiratory distress syndromeVan Eyck et al.1R169Q/R169QAfrican/ Caucasian6 mNoNoHaemorrhagic strokeSplenomegalyPancytopenia, hypoIg, lymphadenopathy, recurrent viral infectionsNANANoNo2R169Q/R169QAfrican/ Caucasian5 mNoNoTIABowel perforation (ulcerative bowel disease, no signs of vasculitis)Leucopoenia, hypoIg, lymphadenopathy, recurrent viral infectionsNANANoNoBelot et al.1R169Q/P193LEuropean CaucasianFirst yearYesLivedo reticularis, ulceration of extremitiesTIA, ischemic stroke, sensitive polyneuropathy, intracerebral haemorrhage.Bowel stenosisHypoIgnegnegNoOral aphtae2G47R/G47RAsian1 mYesErythema nodosum, vasculitic rashIntracerebral haemorrhage, Ischemic stroke, Optic neuritisNoNoNANAYesDactylitis, aneurysm of abdominal vesselsWestendorp et al.1R169Q/R169QEuropean Caucasian3 yNoLivedo reticularis, nodulesIschemic stroke, peripheral neuropathy\
neurosensorial hearing lossNoNoNANANoNo2R169Q/R169QEuropean Caucasian2 yNoLivedo reticularisIschemic strokeNoNoNANANoAutismGonzales Santiago et al.1K13del/N328KEuropean Caucasian2 yYesLivedo racemosaNoNoHypoIgNAnegNoNo2K13del/N328KEuropean Caucasian5 yNoNodules, erytema of lower extremitiesNoNoHypoIg, recurrent infectionsNANANoNoBatu et al.1G47R/G47RTurkish6,5 yYesLivedo reticularis,NoAbdominal painNoNANANoNo2G47R/G47RTurkish4 yYesLivedo reticularis, erythema nodosum, necrotic ulcersStrokeAbdominal pain, hypertransaminasemiaNoposNAYesGlomerulosclerosis3G47R/G47RTurkish10 yYesLivedo reticularisNoAbdominal painNoNANANoNoVan Montfrans et al.1R169Q/R169QEuropean Caucasian1 yYesLivedo reticularis, erythema nodosum, eczema, Raynaud phenomenonIschemic stroke, III cranial nerve paralysisAbdominal pain, hepatomegalyAdenopathy, hypoIg, pancytopenianegnegNoOral aphtae, arthralgia\
GH deficiency2R169Q/R169QEuropean CaucasianBirthNoLivedo reticularis, eczemaNoAbdominal pain, hepatomegaly, splenomegalyHypoIg, anaemiaNDNDNoJugular vein thrombosis, GH deficiency3R169Q/R169QEuropean Caucasian6 yNoLivedo reticularis, ulceration of extremities and trunkNoHepatomegaly, splenomegalyAdenopathy, anaemianegnegNoNo4R169Q/R169QEuropean Caucasian3 yNoLivedo racemosa, erythema nodosum, Raynaud phenomenonIschemic stroke, VI cranial nerve paralysisHepatomegaly, splenomegalyHypoIg, recurrent infections, anaemianegnegNoNo5R169Q/R169QEuropean Caucasian1yNoEczemaIschemic stroke, IV cranial nerve paralysisSplenomegalyHypoIg, anaemia, leucopoenianegNDNoAutism6R169Q/R169QEuropean Caucasian9 mYesEczemaIschemic stroke, IV cranial nerve paralysisAbdominal pain, hepatomegaly, splenomegalyHypoIg, pancytopeniaposposYesOral aphtae, arthralgia7R169Q/R169QEuropean Caucasian8 yYesRashIschemic stroke, III cranial nerve paralysisAbdominal pain, acute liver failureHypoIg, recurrent infections, anaemia,lymphopenianegnegNoOral aphtae, arthralgia8R169Q/R169QAfrican/Caucasian6 mNoEczemaIntracranial haemorrhageHepatomegaly, splenomegalyHypoIg, adenopath, thrombocytopenia, leucopoenianegnegNoNo9R169Q/R169QAfrican/Caucasian5 mNoNoNoBowel ulcerations, colitis, hepatomegaly, splenomegalyHypoIg, recurrent infections, adenopathynegnegNoNoFellmann et al.1Homozygous 22q11.1 deletion (*IL17RA* and *CECR1*)AsianBirth (Died 16 y)NoIchthyosiform rash, oro-vaginal ulcerationsNoNoRecurrent infection (C. Albicans, S. aureus), neutropenianegnegNoChronic systemic inflammation, failure to thrive2Homozygous 22q11.1 deletion (*IL17RA* and *CECR1*)Asian2 yNoIchthyosiform rashNoSplenomegalyOro-vaginal candidiasis, Staphylococcal skin infectionsnegnegNoRetinal vasculitisSchepp et al.1R169Q/\
M243RNA18 yNoNoNoSplenomegalyHypoIg, recurrent respiratory infectionsNANANoArthralgia2R169Q/M243RNA2 m (Died 17 y)YesErythema nodosumIntracranial haemorrhageSplenomegalyHypoIg, lymphopenia, recurrent urinary tract and respiratory infectionsnegNANoArthritis\
Failure to thrive.Legend: *CNS* central nervous system*PNS* peripheral nervous system*TIA* transitory ischemic attack*GH* growth hormone*HypoIg* Hypogammaglobulinemia*ND* not done*NA* not availableTable 3genotype/phenotype correlation in DADA2MutationExonN° of patientsAssociated symptoms (% of patients)M1T21 in heterozygosisFever\
Skin: Non-Langerhans cell histiocytosis\
CNS/PNS: ischemic stroke\
Visceral: involvement: hepatomegaly, splenomegaly. portal hypertension, hypertension (100 %)K13del22 in heterozygosisFever (50 %)\
Skin: Livedo racemosa (50 %), skin nodules (50 %)\
Immune/hematologic system: hypogammaglobulinemia (100 %), recurrent infections (50 %)28-kb-deletion21 in heterozygosisFever\
Skin: Livedo reticularis, urticarial rash\
CNS/PNS: ischemic and haemorrhagic strokes\
Visceral involvement: hepatomegaly, splenomegaly. chronic gastritis\
Immune/hematologic system: leukopenia, hypogammaglobulinemia (100 %)G47R227 in homozygosisFever (64 %)\
Skin: Livedo reticularis (60 %), skin nodules (35 %), ulcerations at extremities/digital necrosis (32 %), Raynaud's phenomenon (28 %), purpuric/vasculitic rash (18 %), erythema nodosum (18 %), panniculitis (3 %)\
CNS/PNS: ischemic stroke (21 %), hemorrhagic stroke (7 %), intracranial haemorrhage (11 %), cranial nerve paralysis (14 %), polineuropathy (11 %), neurosensorial hearing loss (3 %).\
Visceral involvement: abdominal pain (21 %), intestinal vasculitis (14 %), hepatomegaly (3 %), splenomegaly (7 %), hypertransaminasemia (3 %), hypertension (25 %).\
Immune/hematologic system: Leucopoenia (3 %), anaemia (3 %), lymphadenopathy (3 %).1 in heterozygosisG47A22 in heterozygosisFever (100 %)\
Skin: Livedo reticularis (100 %), urticarial rash (100 %)\
CNS/PNS: ischemic and haemorrhagic strokes (100 %)\
Visceral involvement: hepatomegaly (100 %), splenomegaly (100 %), portal hypertension (100 %)\
Immune/hematologic system: Pancytopenia (100 %), hypogammaglobulinemia (100 %).G47V21 in heterozygosisFever\
Skin: Livedo reticularis\
Visceral involvement: hypertension, abdominal and renal aneurysm (100 %).I93T21 in heterozygosisFever\
Skin: Non-Langerhans cell histiocytosis\
CNS/PNS: ischemic stroke\
Visceral: involvement: hepatomegaly, splenomegaly. portal hypertension, hypertension (100 %)A109D31 in heterozygosisFever\
Skin: Livedo reticularis\
CNS/PNS: ischemic stroke\
Visceral involvement: splenomegaly (100 %).H112Q31 in heterozygosisFever\
Skin: Livedo reticularis, urticarial rash\
CNS/PNS: ischemic and haemorrhagic strokes\
Visceral involvement: hepatomegaly, splenomegaly, portal hypertension\
Immune/hematologic system: Pancytopenia, hypogammaglobulinemia (100 %).T119A34 in heterozygosisFever (100 %)\
Skin: Livedo reticularis, ulceration of extremities (100 %)\
CNS/PNS: ischemic and haemorrhagic strokes (100 %)G142S34 in heterozygosisFever (100 %)\
Skin: Livedo reticularis, ulceration of extremities (100 %)\
CNS/PNS: ischemic and haemorrhagic strokes (100 %)R169Q315 in homozygosisFever (37 %)\
Skin: Livedo reticularis (58 %), skin nodules (4 %), ulcerations at extremities/digital necrosis (8 %), Raynaud's phenomenon (8 %), purpuric/vasculitic rash (13 %), erythema nodosum (13 %), eczema (20 %)\
CNS/PNS: ischemic stroke (54 %), hemorrhagic stroke (13 %), intracranial haemorrhage (13 %), cranial nerve paralysis (37 %), polineuropathy (8 %), neurosensorial hearing loss (8 %).\
Visceral involvement: abdominal pain (17 %), bowel ulcerations (8 %), chronic gastritis (4 %), bowel stenosis (4 %), colitis (4 %), hepatomegaly (45 %), splenomegaly (58 %), acute liver failure (4 %), hypertension (8 %).\
Immune/hematologic system: hypogammaglobulinemia (62 %), pancytopenia (8 %), leucopoenia (20 %), lymphopenia (13 %), granulocytopenia (4 %), anaemia (25 %), thrombocytopenia (4 %),\
lymphadenopathy (25 %), recurrent infections (29 %).9 in heterozygosisP193L41 in heterozygosisFever\
Skin: Livedo reticularis, ulcerations at extremities\
CNS/PNS: ischemic stroke, TIA, intracranial haemorrhage, polineuropathy\
Visceral involvement: bowel stenosis, oral aphtae\
Immune/hematologic system: hypogammaglobulinemia (100 %).M243R42 in heterozygosisFever (50 %)\
Skin: erythema nodosum (50 %)\
CNS/PNS: intracranial haemorrhage (50 %)\
Visceral involvement: splenomegaly (100 %)\
Immune/hematologic system: hypogammaglobulinemia (100 %), recurrent infections (100 %).P251L44 in heterozygosisFever (25 %)\
Skin: Livedo reticularis (75 %), vasculitic rash (50 %)\
CNS/PNS: ischemic stroke (75 %), cranial nerve paralysis (100 %), neurosensorial hearing loss (25 %).\
Visceral involvement: hypertension (25 %), epididymitis (25 %)W264S51 in heterozygosisFever\
Skin: Livedo reticularis\
Visceral involvement: hypertension, abdominal and renal aneurysm (100 %).R306\*61 in heterozygosisFever\
Skin: rash\
CNS/PNS: ischemic stroke, hemorrhagic stroke, intracranial haemorrhage (100 %)N328K72 in heterozygosisFever (50 %)\
Skin: Livedo racemosa (50 %), skin nodules (50 %)\
Immune/hematologic system: hypogammaglobulinemia (100 %), recurrent infections (50 %)Y453C93 in heterozygosisFever (100 %)\
Skin: Livedo reticularis (100 %), urticarial rash (33 %)\
CNS/PNS: ischemic stroke (100 %), haemorrhagic strokes (33 %)\
Visceral involvement: hepatomegaly (66 %), splenomegaly (100 %), portal hypertension (33 %)\
Immune/hematologic system: Pancytopenia (66 %), hypogammaglobulinemia (66 %).

In most patients, a neurological involvement, affecting both the peripheral and central nervous system, has been described.

The severity of the CNS involvement is rather variable. In some patients a transitorily ischemic attack (TIA) has been described (with negative cerebral CT and/or MRI), while others developed an ischemic or hemorrhagic stroke (in few cases a ventricular haemorrhage has also been detected). Typically, the strokes associated to DADA2 are lacunar with a wide range of clinical manifestations ranging from clinically silent episodes in few cases, to severe ones leading to a permanent disability \[[@CR1], [@CR2], [@CR10], [@CR12]\].

The neuropathy ranges from a transient mononeuritis (such as a cranial nerve transient paralysis) to a permanent polyneuropathy; moreover, few patients suffered from optic neuritis. In few cases, persistent neurosensorial hearing loss has also been described \[[@CR1], [@CR2], [@CR12]\].

Most patients have gastrointestinal manifestations: abdominal pain, significant weight loss, chronic gastritis, hepatomegaly, splenomegaly, portal hypertension, bowel perforation or stenosis.

While nephrogenic hypertension is rather common in this condition, in few patients focal glomerulosclerosis and renal amyloidosis have also been described \[[@CR11]\]. Lung involvement with necrotising pneumonia (lethal) has been reported in one patient \[[@CR11]\].

The blood tests usually reveal an elevation of acute phase reactants (ERS, CRP), low haemoglobin levels and neutrophilic leukocytosis \[[@CR1], [@CR2]\]; however in few patients cytopenia (pancytopenia, leucopoenia) has been detected \[[@CR1], [@CR7], [@CR12]\]. Auto-antibody are usually negative.

As stated above, a mild immunodeficiency can be observed; some patients present hypogammaglobulinemia that may affect IgM or all Ig subclasses \[[@CR1], [@CR13]\]. Of note, despite the low immunoglobulins' levels, only few cases displayed an increased susceptibility to infections, that was rather severe in exceptional cases \[[@CR1], [@CR3], [@CR7], [@CR12], [@CR13]\].

MRI is the most useful tool in the diagnosis of cerebral strokes; in fact CT scan as well as conventional angiography may not detect the smaller lacunar strokes and therefore underestimate the entity of involvement of the CNS \[[@CR1]\].

Some patients underwent an angiographic investigation, that revealed the presence of stenosis and/or aneurysms of abdominal artery, particularly mesenteric, celiac, hepatic and renal arteries; the histological analysis, when done, revealed a necrotizing vasculitis \[[@CR1], [@CR2]\].

In patients with symptoms suggestive for organ involvement but without pathologic finding in not-invasive radiologic studies, conventional angiography can be of help revealing aneurism and or stenosis in the middle sizes arteries.

Skin biopsy revealed, in most cases, a non-granulomatous, necrotizing vasculitis of small and medium-sized vessels, with the same histopathologic features of polyarteritis nodosa \[[@CR1], [@CR2], [@CR9]\].

In few cases the histology was less specific showing a leucocytoclastic vasculitis or a panniculitis.

Polyarteritis nodosa (PAN) is, according to the Chapel Hill classification, a "Necrotizing arteritis of medium or small arteries without glomerulonephritis or vasculitis in arterioles, capillaries, or venules, and not associated with antineutrophil cytoplasmic antibodies (ANCAs)" \[[@CR22]\]. It's gathered in the medium-sized vessels vasculitis, even if it can affect arteries of any size \[[@CR22]\].

Being DADA2 a vasculitis with a genetic basis, it has been proposed to group this disease in the vasculitis with a probable cause according to the Chapel Hill classification \[[@CR11], [@CR22]\].

Notably, most of the DADA2 patients not only received the histological diagnosis of PAN but also met the EULAR/PRINTO/PRES diagnostic criteria for childhood polyarteritis nodosa (Table [4](#Tab4){ref-type="table"}) \[[@CR23]\].Table 4EULAR/PRINTO/PRES classification criteria for childhood Polyarteritis nodosa (PAN) \[[@CR23]\]Histopathology or angiographic abnormalities (mandatory) plus one of the five following criteria:- Histology: necrotising vasculitis in medium or small-sized arteries.\
- Angiography: aneurysm, stenosis or occlusion of a medium or small sized artery,EULAR/PRINTO/PRES classification criteria for childhood Polyarteritis nodosa (c-PAN)1. Skin involvementLivedo reticularis, skin nodules, superficial ulcers, peripheral tissue necrosis2. Myalgia/muscle tendernessMuscle pain or tenderness3. HypertensionBlood pressure \> 95th centile4. Peripheral neuropathySensory or motor neuropathy5. Renal involvementProteinuria, haematuria, impaired function

Unusual phenotypes {#Sec5}
------------------

Even if most of the patients with DADA2 have a clinical phenotype consistent with a systemic inflammatory vasculopathy, a recent report has enlighten that the disease may be dominated by clinical manifestations suggestive for an immune-disrective condition, such as cytopenia, lymphadenopathy, hepatosplenomegaly and immunodeficiency with severe viral infections \[[@CR7]\]. The two patients described did not present skin involvement and one of them developed a vascular involvement only after bone-marrow transplantation. Of note, the mutations found in these two patients were the same described in patients with a "typical" inflammatory clinical picture.

Similarly a third patient with a lymphoprolipherative clinical picture, resembling Castleman's syndrome, has been reported by the same group \[[@CR5]\].

A more recent clinical series of 9 DADA2 patients with the homozygous R169Q mutation has enlightened that the presence of cytopenia is a common finding of the disease, together with the common inflammatory manifestations \[[@CR12]\].

In the two patients carrying homozygous 22q11.1 deletion, encompassing both copies of the IL-17 receptor A (*IL17RA*) and the *CECR1* gene, the clinical phenotype was dominated by muco-cutaneous infections and dermatitis associated to persistent inflammation and, in one patient, vasculitis responding to steroids \[[@CR14]\]. Livedo reticularis, stroke and other DADA2 clinical manifestations were not described.

Finally two brothers with a clinical picture consistent with the diagnosis of common variable immunodeficiency (CVID) were found to be affected by DADA2 by whole exome-sequencing; of note only one of them displayed clinical sign and symptoms consistent with a vasculopathy \[[@CR13]\].

Outcome {#Sec6}
-------

Being a disease of recent identification, the clinical outcome has not been well investigated. However, from the clinical data by now available is clear that the spectrum of severity of the disease is wide, ranging from patients with neonatal onset and a severe organ involvement to patients with onset in the adulthood and the presence of only skin manifestations (Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}); of note, even between patients carrying the same mutations in *CECR1* gene the clinical picture can be widely different (Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}).

The disease turned out to be lethal in seven out of the 65 patients by now described \[[@CR1], [@CR2], [@CR6], [@CR13], [@CR14]\]: in three cases the severity of the visceral involvement was lethal \[[@CR1], [@CR2]\], two patients died for respiratory complications following intracranial haemorrhage \[[@CR6], [@CR13]\], while one patient developed necrotising pneumonia \[[@CR1], [@CR11]\]; finally one of the two patients carrying the homozygous deletion on 22.11.1 chromosome died for septic shock.

Treatment {#Sec7}
---------

DADA2 is a newly recognised condition and the number of patients so far described is limited; for this reason the response to treatment is largely anecdotal and still controversial (Table [5](#Tab5){ref-type="table"}).Table 5Treatment administrated and clinical response in the described DADA2 patients (1-14)TherapyCase report (number of treated patients)Response to treatmentSteroids (orally or i.v.)Navon et al. (17)In 2 cases complete control of the disease with on demand steroidal therapy. In other patients steroid-dependence.Zhou et al. (9)Partial control of diseases manifestations with high doses of corticosteroidsVan Eyck et al. (2)Steroid-dependenceBelot et al. (2)Steroid-dependenceGarg et al. (1)Steroid-dependenceVan Montfrans et al. (6)Partial response in 3 patientsSchepp et al. (1)Partial responsecyclophosphamide (orally or i.v.)Navon et al. (9)Good response in 2 patients.Zhou et al. (7)Not specifiedBelot et al. (2)Partial responseGarg et al. (1)Poor responseBatu et al. (4)Poor responseAzathioprineNavon et al. (7)No patients with complete responseVan Eyck et al. (2)Poor responseBelot et al. (1)Good response in association to methotrexateBatu et al. (3)Poor responseVan Montfrans et al. (5)Not specifiedMethotrexateNavon et al. (3)Good response in association with other immunosuppressive and biologicsBelot et al. (1)Good response in association with azathioprineBatu et al. (3)Poor responseSchepp et al. (1)Partial responseCyclosporineVan Eyck et al. (1)Poor responseColchicineBatu et al. (5)Good response in one patient, none response in 4 patientsMycophenolateZhou et al. (2)Not specifiedVan Eyck et al. (1)Poor responseBelot et al. (1)Partial response in association with cyclophosphamideBatu et al. (2)Good response in one patient, poor in the otherSirolimusVan Eyck et al. (2)Good response in one patient\
Poor response in one patientTacrolimusVan Eyck et al. (2)Good response in one patient\
Poor response in one patientI.v. immunoglobulinsNavon et al. (1)Not specifiedZhou et al. (5)Not specifiedVan Eyck et al. (2)Prophylactic dosageBelot et al. (1)Prophylactic dosageSchepp et al. (2)Prophylactic dosageAnakinraZhou et al. (5)Not specifiedGarg et al. (1)Initial partial response than relapseVan Montfrans et al. (1)Good responseCanakinumabGarg et al. (1)Initial partial response than relapseEtanerceptNavon et al. (5)Complete response in 5 patients\
Partial response in 1 patientZhou et al. (6)Not specifiedvan Montfrans et al. (3)Partial response in 1 pateint\
Complete response in 2 patientsBatu et al. (3)Partial response in 2 patients, complete in 1AdalimumabNavon et al. (3)Complete response in 2 patients, exacerbation in 1 patientInfliximabNavon et al. (2)Complete response in 1 patient\
Partial response in 1 patientTocilizumabZhou et al. (1)Not specifiedVan Eyck et al. (1)Complete responseBatu et al. (1)Poor responseRituximabZhou et al. (1)Poor responseBelot et al. (1)Poor response

Being an inflammatory condition, high doses of steroids are usually able to control the clinical manifestations \[[@CR1], [@CR2], [@CR8], [@CR9], [@CR11], [@CR12]\]. However, due to the severity of the condition, a steroid-dependence is often described. None of the most common immunosuppressive drugs (cyclophosphamide, azathioprine, methotrexate) was effective \[[@CR1], [@CR2], [@CR6], [@CR8], [@CR11], [@CR13]\].

Navon et al. reported ten patients treated with anti-TNF drugs (etanercept, adalimumab, infliximab) with complete response in 8, even after the failure of immunosuppressive therapies \[[@CR2]\]; good results with anti-TNF agents were also reported in other small series \[[@CR3], [@CR11], [@CR12]\]. By now, the reason why this drug is effective is still unclear.

According to the report of Zhou et al., neither immunosuppressive nor biologic drugs were able to completely control the disease manifestations in all treated patients; the enzymatic substitutive treatment (fresh frozen plasma or recombinant enzyme) was postulated to be of help. This approach was tempted in two patients reported by Batu et al. with a transient good response in one and a not-satisfactory response in the other \[[@CR11]\].

A possible role of hematopoietic stem cell transplantation (HSCT) has been postulated to be effective by Zhou et al. and Navon et al., being able to provide ADA2 producing monocytes and therefore to normalize the plasmatic levels of the enzyme \[[@CR1], [@CR2]\]. This therapeutic strategy, performed in one of the two patients reported by Van Eyck et al. \[[@CR7]\] and in a patient reported by the NIH group \[[@CR3]\], was able to normalize the plasmatic levels of ADA2 and to control the disease manifestations \[[@CR3], [@CR7]\]; early complications occurred in one of them. More recently two additive patients who displayed a complete response to HSCT have been described \[[@CR12]\].

Van Eyck et al. conclude that HSCT should be suggested only for those patients with a severe disease, since DADA2 patients present an increased risk of HSCT-related complications due to the persistent inflammation and the compromised endothelial integrity \[[@CR7]\]. Of note, the other patient described in this paper displayed a complete response to treatment with sirolimus; the authors assume that this drug may be of help in the control of the clinical manifestations related to ADA2-deficiency, being able to reduce the M1 macrophage differentiation and the production of IL-6 \[[@CR7]\].

Conclusion {#Sec8}
==========

In conclusion DADA2 is a genetic condition mainly characterized by an inflammatory vasculopathy resembling polyarteritis nodosa (PAN). From the clinical data so far available, the age at onset, the disease manifestations and severity are widely variable. Further clinical studies are therefore needed in order to better understand the phenotypic viability of this condition and the genotype-phenotype correlation.

In light of the data by now available, we consider the genetic analysis of *CECR1* gene suggested in the following clinical pictures: patients with an inflammatory vasculopathy with early onset in infancy, patients with a diagnosis of PAN or cPAN with early onset and/or severe organ involvement (above all stroke), especially in case of a positive family history or consanguinity/endogamy in the parents. Moreover DADA2 should be ruled out in patients with an immune-disreactive condition without an underlying diagnosis, especially in presence of signs or symptoms of vasculitis.

Finally, a better enlightenment of the pathogenetic mechanisms of the disease is needed; these data will be of help also in the identification of an effective treatment.
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